Status:
UNKNOWN
ARMA (Antireflux Mucosa Ablation) in Patients With Chronic Refractory Reflux Disease
Lead Sponsor:
Klinikum Garmisch-Patenkirchen
Conditions:
Gastro-esophageal Reflux
Reflux, Gastroesophageal
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
Pilot study of the possible clinical response to anti reflux mucosal ablation in patients with chronic refractory reflux disease
Detailed Description
Prospective, non-controlled, monocentric pilot study in patients with therapy-refractory reflux symptoms under proton pump inhibitor (PPI) therapy or intolerance of the necessary therapy or rapid recu...
Eligibility Criteria
Inclusion
- typical reflux symptoms more than 2x per week during PPI therapy more than 6 month
- proof of gastro-esophageal reflux in pH metry oder pH/Impedance measurement
Exclusion
- age \< 18 y
- primary motility disorder of the esophagus
- hiatal hernia \> 3 cm
- Hill classification \> III
- pregnancy
- coagulation disorder
- mandatory intake of oral anticoagulation drugs
Key Trial Info
Start Date :
July 14 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2023
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT05425771
Start Date
July 14 2022
End Date
May 31 2023
Last Update
July 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Klinikum Garmisch-Partenkirchen
Garmisch-Partenkirchen, Bavaria, Germany, 82467